Quick Facts

• May be utilized for the temporary relief of symptoms associated with seasonal allergic rhinitis.
• Provides symptomatic support for nasal congestion and stuffiness.
• Assists in addressing symptoms of hay fever, such as sneezing and a runny nose.

---

Clarinase Repetabs is a therapeutic option used for the temporary relief of symptoms that may be associated with seasonal allergic rhinitis, commonly referred to as hay fever. It is primarily indicated for situations where both antihistamine properties and nasal decongestant activity are desired to manage the full range of symptoms.

This compound may assist in providing symptomatic support for various manifestations of allergies, including sneezing, a runny nose (rhinorrhea), and watery, itchy eyes (lacrimation and pruritus). The formulation is also utilized to help address nasal congestion or stuffiness that often accompanies these allergic reactions. Consult with a healthcare professional to determine if this product is appropriate for your specific supportive needs.

It is important to adhere to a healthcare provider's guidance regarding use and duration of treatment. This medication may support individuals seeking relief during periods of increased seasonal allergen exposure.

Who Can and Cannot Use Clarinase Repetabs?

The official eligibility for Clarinase Repetabs is strictly defined by regulatory bodies based on age, concurrent medication, and pre-existing health status. The medicine is officially indicated for use only in adults and adolescents aged 12 years and over.

---

Absolute Contraindications (Must Not Use)

Use is formally contraindicated in patients with a history of hypersensitivity to the ingredients, or for those with specific conditions that could be worsened by the pseudoephedrine component. These include:

• Patients receiving Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of cessation.
• Patients with severe hypertension or severe coronary artery disease.
• Patients with narrow-angle glaucoma, urinary retention, hyperthyroidism, pheochromocytoma, or severe renal disease.

---

Restricted or Not Recommended Populations

Clarinase Repetabs is generally not recommended for the following populations as safety and efficacy are not established or due to increased risk profile:

• Children under 12 years of age.
• Patients above 60 years of age.
• Individuals with impaired renal function or impaired hepatic function.
• Women who are pregnant or breastfeeding.

The official regulatory profile for Clarinase Repetabs details specific restrictions and warnings regarding co-administration with other medicines and products. The most severe constraints involve Contraindicated Combinations due to the risk of significant adverse effects.

Co-administration is strictly prohibited with Monoamine Oxidase Inhibitors (MAOIs), including use within fourteen days of stopping MAOI therapy, due to the potential for a severe increase in blood pressure. The product is also contraindicated with certain Ergot Alkaloids and other Sympathomimetic Amines (such as other decongestants) to prevent additive vasoconstricting or stimulating effects.

---

Documented Interaction Patterns

Interaction Type	Interacting Agent	Official Regulatory Statement
Pharmacokinetic	Ketoconazole, Erythromycin, Cimetidine	These CYP inhibitors increase the plasma concentration of loratadine, though this effect is generally reported as without clinical significance.
Pharmacodynamic	Antihypertensive Agents	The pseudoephedrine component may reduce the antihypertensive effects of drugs that influence the sympathetic system.
Pharmacodynamic	CNS Depressants and Alcohol	The antihistamine component may enhance the CNS depressant effect of co-administered substances, including alcohol.
Procedural	Skin Testing Procedures	The product must be stopped 48 hours before skin tests, as the antihistamine component may diminish the diagnostic effect of the test.
Population-Specific	Severe Hepatic Insufficiency	Use of the fixed combination should generally be avoided due to the altered clearance rates of the active ingredients in this population.

The regulatory profile strictly outlines constraints on use to manage the risk of pharmacodynamic reinforcement and documented exposure modification.

The mechanism of action of this product relies on dual-pathway modulation exerted by its two active components: Loratadine and Pseudoephedrine.

Blocking the Histamine-Mediated Inflammatory Cascade

The Loratadine component is a selective, competitive antagonist of peripheral Histamine H1 receptors. By occupying these sites primarily outside the central nervous system, the molecule prevents the inflammatory mediator histamine from binding and activating its target receptors. This molecular interference modifies the early steps of the inflammatory cascade, leading to the maintenance of capillary permeability and limitation of excessive fluid leakage from blood vessels, which influences fluid-related tissue changes.

Modulating Vascular Tone via alpha-Adrenergic Receptors

The Pseudoephedrine component is a sympathomimetic agent that functions as an agonist of alpha1-adrenergic receptors present on the smooth muscle lining the arterioles of the nasal mucosa. This action, supported by the concurrent release of endogenous norepinephrine, causes the smooth muscle to contract. The resulting vasoconstriction physically reduces the blood volume and pressure within the nasal tissues, which is the direct physiological mechanism for reducing local tissue fluid content. This simultaneous action on both the chemical signaling and the vascular dynamics results in a coordinated modulation of the two key physiological systems involved.

The administration of Clarinase Repetabs involves its use as a prolonged-release tablet taken by the oral route. The standard regimen for adults and adolescents 12 years of age and older is a dose of one tablet containing Loratadine 5 mg and Pseudoephedrine Sulfate 120 mg. This dosage is intended to be taken twice daily, maintaining an approximate 12-hour interval between administrations, which defines the maximum daily utilization.

Due to the tablet's extended-release design, it is important that the tablet is swallowed entirely with water; it must not be chewed, crushed, or broken to ensure the active ingredients are released over the intended duration. Intake is permitted without regard to mealtimes.

This fixed-combination product is intended as a short-term intervention. Treatment is generally limited to approximately 10 days, and its continuation is not recommended once the underlying symptoms have resolved. Furthermore, specific administrative considerations are required for certain populations. The medicine is not generally recommended for use in children under 12 years or for adults over 60 years. For patients diagnosed with severe renal impairment, a dose reduction to one tablet per day is typically advised to prevent potential accumulation of the active ingredients.

Research Evidence / Overview of Studies for Clarinase Repetabs

Evidence for Symptomatic Relief of Seasonal Allergic Rhinitis

Research on this combination product was primarily conducted through short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms typical of seasonal allergic rhinitis, a condition characterized by episodic manifestations. The research examined outcomes related to physical discomfort, specifically patient-reported scores for nasal congestion, runny nose, and sneezing. Trials included adults and adolescents who were experiencing periods of heightened symptom activity. Studies monitored how symptoms evolved in the observed populations during the study periods, and findings describe patterns observed in the measured symptom scores across the study group.

Comparative Research and the Extended-Release Formulation

Studies also explored the combination product against its individual components (loratadine alone or pseudoephedrine alone). Trials reported how symptoms evolved in these different groups over defined time intervals. The research also includes specific bioequivalence studies applied to the extended-release Repetabs formulation. These regulatory studies were designed to examine the release profile of the medicine, which evaluates the release profile of the components over time. This research is relevant in trials assessing short-term or episodic symptom patterns. The findings contribute to research exploring the combined profile of the two components.

Evidence in Specific Patient Groups

The primary research focused on adults and adolescents (12 years of age and older). The evidence is focused primarily on the populations studied. Research has also explored the compound in specific groups with conditions marked by functional limitations, such as mild hepatic (liver) or renal (kidney) impairment. However, data for certain groups, particularly those with severe impairment, remain insufficient, and subgroup findings are limited.

Long-Term Outcomes and Follow-Up Duration

Research exploring short-term symptom changes typically observed responses over defined time intervals relevant to the allergy season. Consequently, follow-up durations were limited in the core trials. Long-term outcomes, such as how symptom patterns evolve beyond several weeks, are not fully established. There is limited information for long-term outcomes to contextualize how patients reported their experience over extended periods.

What is Still Uncertain in the Research Record

Evidence highlights what is known—and what is still uncertain. Several key areas require further research. Specifically, studies focusing on episodes where symptoms become more noticeable have not included children under 12 years of age; outcomes are not fully characterized for this group. Additionally, while some evidence exists for mild organ impairment, data for certain groups with severe hepatic or renal conditions remain insufficient. Comparative evidence is limited in many subgroups, and research continues to contribute to the overall evidence landscape. The study results reflect the specific conditions under which they were conducted and findings describe group patterns, not personal outcomes.

Common questions about Clarinase Repetabs (FAQ)

---

Q: How quickly should I expect Clarinase Repetabs to start working?

Regulatory studies on the components of Clarinase Repetabs indicate that the anti-histaminic effect of loratadine typically begins within one to three hours after administration. This timeline describes the onset of anti-histaminic activity, though the overall relief experience may vary between individuals.

---

Q: How long does the effect of one Clarinase Repetabs tablet last?

The product is specifically formulated as a 12-hour extended-release tablet, which is referred to as a Repetab. This sustained action design is intended to deliver continuous relief. The delivery system is intended to support administration at a 12-hour interval.

---

Q: Is there a maximum number of days Clarinase Repetabs should be used continuously?

Official guidelines structure the use of this fixed-combination product as a short-term intervention, with treatment generally advised to be limited to approximately 10 days. Official guidelines structure the discontinuation of use once the underlying symptoms have resolved.

---

Q: Why do official documents warn against taking Clarinase Repetabs close to bedtime?

The product contains pseudoephedrine, which is classified as a central nervous system stimulant. Sleeplessness (insomnia) is listed in regulatory documents as a potential side effect. Official documentation notes that taking the dose close to bedtime may increase the risk of sleep disruption.

---

Q: Does alcohol consumption change the effects of Clarinase Repetabs?

Official product information notes that the antihistamine component in this medicine may enhance the central nervous system (CNS) depressant effect of other substances. This means that if alcohol is co-administered, it may potentially increase the risk of CNS depression.

---

Q: Are there specific warnings for women who are breastfeeding regarding this medicine?

Official guidelines state that use during breastfeeding is generally not recommended. The active components of the medicine may pass into breast milk, and the combination has a potential to negatively affect lactation.

---

Q: What is the difference between Clarinase Repetabs and Claritin?

The key difference lies in the composition of the products. Claritin (loratadine) contains only the antihistamine component. In contrast, Clarinase Repetabs is a combination product that contains both the antihistamine (loratadine) and a decongestant (pseudoephedrine).

---

Q: Can Clarinase Repetabs cause anxiety or jitters?

Regulatory documents have noted reports of adverse reactions that include nervousness, restlessness, and anxiety. These effects are often related to the stimulating properties of the pseudoephedrine component within the medicine.

---

Q: Is it normal to feel a dry mouth after taking Clarinase Repetabs?

Dry mouth is described in regulatory documents as a commonly reported side effect associated with the product. This indicates that it is a known occurrence.

---

Q: Is Clarinase Repetabs the same as a regular decongestant?

No, Clarinase Repetabs is officially classified as a combination product. It is composed of two distinct types of medicine: an antihistamine (loratadine) and a sympathomimetic decongestant (pseudoephedrine).

---

Q: Are there concerns about taking Clarinase Repetabs long-term?

The research evidence for this combination product indicates that follow-up durations in the core trials were limited. Consequently, long-term outcomes for symptom patterns evolving beyond several weeks are not fully established. The product's regulatory indication is generally for short-term use.

---

Q: What if I forget to take a Clarinase Repetabs tablet?

Label instructions define the appropriate action for a missed dose as taking it as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the missed dose should be skipped entirely. Doubling the dose to make up for the missed one is not advised.

---

Q: Does taking Clarinase Repetabs affect sleep patterns?

The product contains the pseudoephedrine component, which is a central nervous system stimulant, and the medicine may affect sleep patterns. Insomnia (difficulty sleeping) is listed as a commonly reported side effect in the official product information.

---

Q: Does the medicine help with eye symptoms of allergies?

Official product information confirms that the product is indicated for the relief of symptoms associated with allergic rhinitis. This includes addressing not only nasal symptoms but also related eye symptoms such as itchy eyes and watery eyes.

---

Q: How is Clarinase Repetabs different from other combination allergy medicines?

The product is factually characterized by its specific composition and its delivery system. It uses a second-generation antihistamine combined with a sympathomimetic decongestant in an extended-release (Repetabs) formulation. This combination formulation is designed for sustained action to support relief over a prolonged period.

---

Q: Does Clarinase Repetabs contain ingredients listed as banned substances in sports?

As a matter of public classification, the pseudoephedrine component is included on the World Anti-Doping Agency (WADA) Prohibited List. This ingredient falls under the category of Stimulants and is listed as prohibited for in-competition use.

---

Q: Can use of Clarinase Repetabs temporarily raise blood pressure?

The pseudoephedrine component is a sympathomimetic agent associated with cardiovascular risks. Regulatory documents list increased blood pressure as a possible side effect. The medicine is contraindicated in patients with severe hypertension.

---

Q: Is Clarinase Repetabs used for chronic sinusitis?

Official product information indicates that the product is primarily intended for the relief of symptoms associated with seasonal allergic rhinitis. Furthermore, the guidelines generally limit the use to short-term intervention.

---

Q: Can Clarinase Repetabs interact with herbal supplements?

Regulatory and official records indicate that the interaction of this product with many herbal remedies and supplements has limited testing. Regulatory records note specific caution regarding supplements that may also cause effects like sleepiness or dry mouth.

---

Q: Can Clarinase Repetabs affect my ability to drive?

Regulatory information generally states that the product does not impair the ability to drive. Official information suggests that one should avoid driving or operating machinery if experiencing side effects such as dizziness or somnolence (sleepiness).

---

Q: Is Clarinase Repetabs recommended for cold symptoms, or just allergies?

The product is indicated in regulatory documents for the relief of symptoms associated with both allergic rhinitis (allergies) and the common cold. This includes treating symptoms such as a runny or stuffy nose and sneezing.

---

Q: Is there a link between Clarinase Repetabs and headache side effects?

According to official regulatory documents, headache is listed as one of the commonly reported side effects associated with the product.

How to Store and Dispose of Clarinase Repetabs

The official storage and disposal guidelines for Clarinase Repetabs define mandatory conditions to maintain the product's stability and ensure safety.

Storage Requirement	Specification
Temperature	Store at controlled room temperature, typically 20 C to 25 C.
Protection	Protect the medication from light, moisture, and excess heat. Do not freeze.
Packaging	Keep the tablets in the original container, tightly closed, and inspect the blister packaging for signs of damage before use.
Child Safety	Keep the product out of the sight and reach of children, utilizing safety caps and storing the medicine in a secure, elevated location.

For disposal, Clarinase Repetabs must not be flushed down the toilet or discarded in wastewater systems. Unused or expired medication should be disposed of via a drug take-back program. If no program is available, follow government guidelines for disposal in household trash, which typically requires mixing the product with an undesirable substance.